Progyny Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Progyny Inc 's ROA in the second quarter of 2026?
Progyny Inc achieved a return on average assets (ROA) of 10.66 % in its second quarter of 2026, which is below Progyny Inc 's average return on assets, which stands at 14.47%.

ROA has improved compared to 9.03% in the first quarter of 2026, due to net income growth.

However, within the Healthcare sector 92 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 674, from total ROA ranking in the first quarter of 2026 at 933.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-5.93 %	-4.37 %	46.17 %	36.76 %	23.54 %
Y / Y Net Income Change	63.93 %	60.91 %	18.54 %	33.04 %	3.8 %
Net Income (TTM) in million	79	68	59	57	53
Return On Assets (TTM)	10.66 %	9.03 %	7.73 %	8.1 %	8.23 %
PGNY's Total Ranking	# 674	# 933	# 792	# 823	# 805
Total Assets (TTM) in million	716	698	742	795	761
Seq. Total Assets Change	2.51 %	-5.94 %	-6.64 %	4.5 %	4.2 %
Seq. Net Income Change	15.76 %	94.09 %	-9.95 %	-18.98 %	13.63 %

PGNY's 5 Years Annual ROA >> Back to PGNY Management Effectiveness >> Compare PGNY ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 5
Sector	# 93
Overall	# 568

Return On Assets Statistics
High	Average	Low
90.65 %	14.47 %	-6.62 %
(Mar 31 2020)		(Jun 30 2020)

Financial Statements
Progyny Inc 's Assets	$ 716 million	PGNY's Balance sheet
Progyny Inc 's Income	$ 28 million	Quarterly PGNY's Income Statement
PGNY's Income by Division		See PGNY's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	46.17 %	-23.9 %	44.73 %	63.52 %	41.42 %
Total Assets in million	742	508	668	461	282
Y / Y Net Income Change	7.7 %	-12.41 %	104.35 %	-53.84 %	41.56 %
Net Income in million	59	54	62	30	66
Annual Return On Assets	7.88 %	10.7 %	9.29 %	6.58 %	23.32 %

PGNY's 5 Years Annual ROA >> Back to PGNY Management Effectiveness >> Compare PGNY ROA to its Competitors

Comment on PGNY's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA deteriorated to 7.88 %, despite annual net income growth of 7.7 % to $58.52 million, from $54.34 million a year ago, as PGNY's assets increase to $742.44 million, by 7.7 %.

More Return On Assets Ratios
PGNY's' Return on Assets at Yahoo Finance
Healthcare Facilities Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
PGNY's Roa Ratio versus Healthcare Facilities Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for PGNY's Competitors
Subscribers only: Roa for Progyny Inc 's Suppliers
Subscribers only: Return On Assets for PGNY's Customers

You may also want to know
PGNY's Roi	PGNY's Inventory Turnover Ratio	PGNY's Growth Rates	PGNY's Dividend Comparisons
	PGNY's Profitability Ratios	PGNY's Asset Turnover Ratio	PGNY's Dividend Growth
PGNY's Roe	PGNY's Valuation Ratios	PGNY's Financial Strength Ratios	PGNY's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
Indivior Pharmaceuticals Inc	28.21 %
Qhslab Inc	27.12 %
Adma Biologics Inc	26.58 %
Mettler toledo International Inc	24.86 %
Medpace Holdings Inc	24.84 %
Caredx Inc	24.81 %
Acadia Pharmaceuticals Inc	24.38 %
Eli Lilly And Company	21.97 %
Innoviva Inc	21.64 %
Vaxart Inc	20.85 %
Zevra Therapeutics Inc	20.39 %
Iradimed Corporation	20.36 %
Protalix Biotherapeutics inc	20.09 %
Pro dex Inc	19.87 %
Electromed Inc	19.39 %
United Therapeutics Corporation	17.98 %
Resmed Inc	17.80 %
Krystal Biotech Inc	17.65 %
Chemed Corporation	17.52 %
Zoetis Inc	17.19 %
Vertex Pharmaceuticals Inc	16.88 %
Halozyme Therapeutics Inc	16.55 %
Alnylam Pharmaceuticals Inc	15.76 %
Intuitive Surgical Inc	15.63 %
Healthcare Services Group Inc	15.21 %
Inspire Medical Systems inc	15.21 %
Dexcom Inc	14.87 %
Neurocrine Biosciences Inc	14.73 %
Entera Bio Ltd	14.60 %
Standard Biotools Inc	14.31 %

Date modified: 2026-08-14T20:54:24+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.